Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia

NCT00694109 is registered in ClinicalTrials.gov with Kastle Therapeutics, LLC as lead sponsor.

NCT NCT00694109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00694109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia
Lead sponsor
Kastle Therapeutics, LLC
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2008
Completion date
September 30, 2014
Enrollment
144 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

congenital abnormalities, dyslipidemias, genetic diseases, inborn, hypercholesterolemia, hypercholesterolemia, autosomal dominant, hyperlipidemias, hyperlipoproteinemia type ii, hyperlipoproteinemias, infant, newborn, diseases, lipid metabolism disorders, lipid metabolism, inborn errors, metabolic diseases, metabolic disorder, metabolism, inborn errors